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Summary 
Vascular cell adhesion molecule 1 (VCAM-1)  mediates extravasation of circulating leukocytes 
into inflamed tissues,  and presumably, plays a role in the immigration of cytotoxic effector 
lymphocytes into tumor metastases. Since metastases are rarely cleared by blood-borne cells from 
the immune system, we asked whether the tumor may escape host defense by interfering with 
the mechanism of effector cell extravasation.  Here we show that in mice and humans, VCAM-1 
expression is repressed on tumor-infiltrating vascular endothelial cells in the lungs. On lung blood 
vessels distant from the  tumor,  VCAM-1  is constitutively expressed.  When melanoma and 
endothelioma cells were cultured on either side of a Nucleopore membrane, the expression  of 
VCAM-1 on the endothelioma cells was inhibited and VCAM-1 gene transcription was suppressed. 
We propose that the downregulation of VCAM-1 is a mechanism by which vascularized melanoma 
and carcinoma avoid invasion by cytotoxic cells of the immune system. 
O 
ver the last decade, adoptive immunotherapy protocols 
for the treatment of metastatic malignancies have been 
developed (1). Lymphocytes  were isolated, expanded in vitro, 
and administered back intravenously to the tumor-bearing 
host. The tumor-reactive lymphocytes then accumulated at 
sites of the metastases  (2) and erradicated the malignancies 
by as yet unknown mechanisms. The selective accumulation 
of tumor-reactive lymphocytes requires  adhesion molecules 
on vascular endothelium that mediate the arrest and extrava- 
sation. Since cellular cytotoxicity, either developed in situ or 
mediated by adoptive immunotherapy protocols, represents 
a fundamental threat to the tumor, escape mechanisms avoiding 
arrest  and extravasation could have  evolved.  Indeed, these 
studies show that the most successful accumulation and re- 
sponses to tumor immunotherapy were obtained when pre- 
treating the tumor-bearing host with cyclophosphamide (1, 2) 
a cytostatic drug well-known to disrupt the endothelial cell 
layer integrity (3). The endothelium may be an effective bar- 
rier disabling cytotoxic cells to reach and kill the tumor. 
Vascular cell adhesion molecule 1 (VCAM-1) is a cytokine- 
inducible endothelial adhesion molecule that plays a major 
role during inflammation. Lungs of mice constitutively ex- 
pressed VCAM-1 on endothelial cells lining large vessels. Since 
VCAM-1 mediates lymphocyte  infiltration (4, 5), one would 
expect that colonization of lung tumor metastases  would 
also be enabled by VCAM-1. We studied the expression  of 
VCAM-1  on LPS- and TNF-c~-activated endothelial cells 
under the influence of melanoma cells. The results reported 
here suggest that B16 melanoma cells inhibit VCAM-1 ex- 
pression  on activated endothelia in vivo and in vitro. The 
phenomenon was also observed in human tumors, indicating 
that this mechanism may be a general one. 
Materials and Methods 
Animals,  Cell Lines, and Human Tissue.  Female  C57BL/6 mice 
were 10o14 wk old. The endothelioma cell line bend. 3 was a 
generous gift of Dr. W. ILisau (Max Planck Institute, Bad Nau- 
helm, Germany). The routine melanoma cell line B16/129-10, was 
kindly provided by Dr. W. Birchmeier (Max Delbr/ick-Centrum, 
Berlin-Buch, Germany), and the 3T3 cells were from the Amer- 
ican Type Culture Collection (ATCC), Rockville, MD. Cells were 
grown in DME (Gibco, Paisley,  Scotland) supplemented  with 10% 
FCS  (Boehringer Mannheim,  Germany) (complete medium). 
Human tissue was taken from biopsies after surgery at the Justus 
Liebig University. Collected specimens  included one primary small 
cell lung carcinoma (male, 68-yr-old), three primary mamma car- 
cinoma (female,  50-61-yr-old), and three primary skin melanomas. 
Antibodies and Other Reagents.  Purified  rat IgG was from  Jackson 
ImmunoResearch  (West Grove, PA). Supernatants of anti-VCAM-1 
hybridoma M/K-2.7 (ATCC) and anti-MECA 32 (a kind gift of 
Dr. E. Butcher, Stanford University School of Medicine, Stanford, 
CA) were used. Mouse anti-human VCAM-1, BBA5, was from 
R&D Systems  Europe Ltd. (Abington, UK). Anti-factor VIII an- 
tiserum was purchased from Behringwerke AG (Marburg, Ger- 
many). The visualizing reagent for FACS  |  analysis (Becton Dick- 
inson & Co., Mountain View, CA) was FITC-conjugated goat 
anti-rat IgG (Jackson ImmunoResearch). 
Human and murine recombinant TNF-~ were kindly provided 
by Dr. W. Lesslauer  (F. Hoffmann-La Roche Ltd., Basel, Switzer- 
land). Human recombinant IL-lc~ was from Dr. P. Lomedico (F. 
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chased  from Difco (Detroit, MI). 
Immunohistochemistry.  Mice were injected intravenously with 
2  x  10  s B16/129-10  melanoma cells. 12 d later, pyrogen-free PBS 
or 15 #g of LPS resuspended in PBS was injected intravenously. 
After 18 h, mice were killed and their lungs dilated by injection 
of FCS via the trachea.  Thereafter, the organ was removed, em- 
bedded and frozen in Tissue-Tek, O.C.T.  compound (Miles Inc., 
Elkart,  IN).  6-#m-thick frozen sections were prepared. 
Immunocytochemistry was carried out using a standard APAAP 
technique (6). The developing reagent was 137 mM N,N-dimethyl 
formamide, 0.4 mM naphtol-AS-BI-phosphate, 1.5 mM Fast Red 
TR salt,  and 0.8 mM tevamisole (all from Sigma Chemical Co., 
St. Louis, MO) in Michaelis buffer (143 mM sodium acetate and 
143 mM 5,5-diethylbarbituric acid). The solution was mixed for 
15 min and filtered before use. After a reaction time of 1 h, the 
sections were counterstained with Mayer's Hematoxylin (Merck, 
Darmstadt, Germany), embedded in Mowiol 4-88 (Hoechst, Frank- 
furt, Germany), examined under a Axiophot microscope (Zeiss, 
Oberkochen, Germany) and photographs were printed with a color 
videoprinter (model UP-500P; Sony, Tokyo, Japan).  The size of 
blood vessels was analyzed with the AxioDocA software (Zeiss). 
Co-culture Experiments.  For co-culturing of bEnd.3 with B16 
or 3T3 cells, a membrane holder device, manufactured at the Basel 
Institute for Immunology's workshop,  was used.  Polycarbonate 
Nucleopore membranes (Costar, Cambridge, MA) with a pore size 
of 0.4 #m were used after pretreating them with 10 N NaOH for 
10 s with subsequent and repeated washing with distilled  water 
until neutral pH was attained. The membranes were then fixed 
between two aluminum plates with a circular hole of 350-mm di- 
ameter held together by two clamps. After assembly, the unit was 
autoclaved  and placed  into petri dishes  (Greiner, Solingen, Ger- 
many). The membranes were then coated with 0.1 mg/ml poly-t- 
lysine (Sigma Chemical Co.) in Dulbecco's PBS for 30 min at 37~ 
washed three times, and the petri dishes filled with 30 ml of com- 
plete medium, so as not to trap air bubbles underneath the mem- 
brane. Approximately 5  x  l0  s bEnd.3 cells in  1.5 ml complete 
medium  were seeded  onto  the coated membrane in  the upper 
chamber of the assembly  and incubated at 37~  where the cells 
attached. For time-kinetic studies, bEnd.3 cells were incubated for 
48, 56, 68, and 72 h. After this, the assembly was turned upside 
down and the upper chamber seeded with 5  x  106 B16 melanoma 
cells. The co-culture was maintained for 24, 16, 4 and 0 h, resulting 
in a total incubation time for bEnd.3 cells of 72 h in all experimental 
groups. Where the bEnd.3 cells were cultured with tumor or con- 
trol cells in  the presence of 10 ng/ml  human TNF-ot,  the en- 
dothelioma cell line was also incubated for a total of 72 h. The 
extent of stimulation by TNF-c~ was dependent on how many times 
bEnd.3 cells have been passaged.  After six to seven passages, the 
capacity of the endothelioma cell line to respond to TNF-a was 
significantly diminished.  All experiments described here were done 
with bEnd.3 cells with comparable low passage numbers. The coin- 
cubations were performed for 4 or 24 h. After completed coincu- 
bation, the endothelioma cells were removed and analyzed as de- 
scribed  in the following section. 
Flow Cytometric Analysis.  Endothelioma cells were detached 
from  the  Nucleopore  membrane  by  incubation  with  0.5  ml 
trypsin/EDTA (Gibco) for 5 min at 37~  After blocking the trypsin 
activity  and  washing  with  complete  medium,  the  cells  were 
processed for FACS  |  analysis as described (7). Flow cytometric anal- 
ysis was performed with a FACScan  |  (Becton Dickinson) using 
logarithmic amplification. The cells were electronically gated to 
exclude dead cells and debris.  Analysis was performed with the 
LYSYS  |  data handling system. 
Reverse-transcribedPCR.  Total RNA from cultured bEnd.3 cells 
was isolated and cDNA synthesized as described elsewhere (8). The 
primers used  for PCR  amplification  of VCAM-1  cDNA were 
5'CTCCCAGGAATACAACGATCY  and  5'AGTTGACAGTGA- 
CAGGTCTCY. For the amplification  of hypoxanthine phosphor- 
ybosyl transferase (HPRT) cDNA, a housekeeping gene, the primers 
used were 5'GCTGGTGAAAAGGACCTCTY  and 5'CACAGG- 
ACTAGAACACCTGCY. The PCR reaction was run over 30 cycles 
after 5 s at 96~  15 s at 50~  and 60 s at 72~  on a thermal 
cycler (AMS Biotechnology, Lugano, Switzerland). For some reac- 
tions, 2.5 ng of mouse genomic DNA was included as an addi- 
tional control. To confirm that the amplified band represents mu- 
rine VCAM-1  cDNA,  single  digests  with HpalI and SstI were 
performed. When digested with HpalI, the resulting bands were, 
as anticipated, 317 and 292 bp; when digested with SstI, bands 
of 450 and 159 bp appeared,  showing that VCAM-1  cDNA was 
indeed amplified. 
DNA isolation, restriction enzyme digestion, and agarose gel 
electrophoresis were performed according to standard  methods. 
Results 
Malignant Melanoma Cells Repress VCAM-I  Expression on 
Venular Endothelial  Cells.  Mice were injected with  highly 
metastasizing B16/129-10 melanoma cells, a subclone of the 
original B16 F1 melanoma. Mice were injected with LPS or 
control PBS 12 d before they were killed. The lungs of these 
animals were analyzed by immunohistochemistry. Endothelial 
cells were identified by labeling lung sections with MECA 
32  mAb  (shown  for  LPS  challenged  mice,  Fig.  1  a). 
The expression of MECA 32 on vascular endothelium within 
metastases appears not to be influenced by the tumor envi- 
ronment (Fig. 1 b). On vascular endothelium, VCAM-1 was 
constitutively expressed in large vessels,  such as arterioles and 
venules (Fig. 1 c), indicating the occurrence of chronic inflam- 
matory reactions in mice held under conventional conditions. 
Considerably less VCAM-1 was expressed on vessels of similar 
size infiltrating melanoma metastases (Fig. 1 d). It seems, that 
the presence of melanoma metastases results in the repres- 
sion of VCAM-1  on adjacent  vascular endothelia.  We ob- 
served that veins measuring less than ,,o80 #m in diameter 
were inhibited in their VCAM-1 expression, but larger vessels 
were not  affected (Fig.  1 d). 
The frequency at which such downregulatory events occur, 
was measured (Table 1). In normal and LPS-stimulated mice 
95  _+  2% of the venules outside metastatic lesions are posi- 
tive for VCAM-1 in the lung. Within B16 metastases, how- 
ever, only 18  _+  2%  of the draining vessels were found to 
be positive for VCAM-1,  indicating that in "o80% of the 
cases,  VCAM-1  expression was repressed by the tumor. 
Melanoma  Cells  Repress  VCAM-1  on  TNF-ce-Stimulated 
Endothelial Cells.  To mimic in vitro the conditions encoun- 
tered on vascular endothelia within tumors, a co-culture system 
was established using B16 melanoma and bEnd.3 endothelioma 
cells. Intimate contact of tumor and endothelial cells was ob- 
tained by incubating both cell types on either side of a 0.4- 
#m Nucleopore filter membrane.  Transmigration of either 
812  Endothelial  Vascular Cell Adhesion Molecule 1 Suppressed by Melanoma Figure  1.  Histochemical staining of endothelial cells in normal and malignant murine lung after LPS-challenge. The animals were treated as described 
in Materials and Methods.  Frozen sections of the lung (6/zm) were labeled with specific antibodies  and developed with alkaline phosphatase-coupled 
secondary antibodies.  (a) Labeling of normal lung by the endothelial  cell-specific mAb MECA 32.  (b) MECA 32 labeling  of a venule within a B16 
melanoma  metastasis.  (c) VCAM-1  staining  by mAb M/K 2.7 showing the same venule as in (a) on a serial section.  (d) VCAM-1  staining  by mAb 
M/K 2.7 showing the same venule as in (b) within a B16 metastasis. (Arrows)  Venules in normal  tissue and metastatic  lesions within the lung of one 
representative  mouse (Experiment #1, n  =  2).  (Arrowheads)  A large vein adjacent  to a metastasis.  Original magnification:  x250; bar,  34/zm. 
Table  1.  Repression of VCAM-I  Expression on  Tumor-draining Endothelia in B16 Melanoma Metastases 
Normal lung  Metastasis 
Experiment  No.  1  2  3  1  2  3 
VCAM-1  269/285  183/189  237/253  34/202  15/96  32/160 
94%  97%  94%  17%  16%  20% 
MECA 32  283/283  193/193  251/251  210/210  83/83  149/149 
100%  100%  100%  100%  100%  100% 
Lungs of B16 tumor-bearing mice were prepared  as described in Materials  and Methods. In Experiment 1, the animals were pretreated  with 15/zg 
of LPS i.v., mice in experiments  2 and 3 were not pretreated.  Immunohistochemical  analysis of blood vessels draining metastases and normal lung 
tissue was performed on frozen sections after labeling for VCAMol or the endothelial  marker MECA 32, respectively.  Blood vessels measuring  <80 
/zm in diameter, but not capillaries, were analyzed. The total tumor areas of 39, 22, or 44 sections were analyzed in experiments  1, 2, or 3, respective- 
ly, for VCAM-1 and MECA 32. Since normal tissue is more abundant  than tumorous tissue,  2, 4, or 4 sectiot~s were analyzed outside metastases. 
Sections stained for VCAM-1 were serial sections of tissues analyzed for MECA 32 expression outside  the tumor. The data are expressed as numbers 
of VCAM-1 or MECA 32 positive vessels/total numbers  of blood vessels. Percentages of positive vessels are indicated underneath.  The data represent 
values  of 2,  8,  and  4  independently  treated mice in experiments  1,  2,  and 3,  respectively. 
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never observed, however direct cell-cell contact by filopodia 
could not  be excluded  (not  shown).  First  we determined 
whether VCAM-1 expression can be upregulated on the en- 
dothelial cell line upon treatment  with either LPS,  IL-lo~, 
human and murine TNF-c~ (not shown). This effect was ob- 
served and was also attained when the endothelial cells were 
grown on Nucleopore filters (shown for TNF-ot treatment, 
Fig.  2,  C  and D).  After co-cuhure of the endothelial cells 
with  the  melanoma  cell  line  in  the  presence  of TNF-ol, 
VCAM-1 expression was lost in a time-dependent fashion. 
Maximal repression  of VCAM-1 expression was obtained after 
24 h (Fig.  2 E  and not shown). However, when endothelial 
cells were co-cultured with the fibroblast cell line 3T3, TNF- 
a-induced VCAM-1 expression persisted (Fig. 2 F), indicating 
that downregulation by melanoma cells is not a mere co-culture 
effect. 
Malignant Melanoma Cells Reduce VCAM-I mRNA Abun- 
dance.  Metastasizing tumor cells are known to secrete pro- 
teolytic enyzmes (9), which may cleave VCAM-1 from en- 
dothelial  cell  surfaces  or,  VCAM-1  expression  could  be 
regulated at the level of transcription.  To analyze the mecha- 
nism, mRNA expression in endothelial cells was assessed by 
RT-PCR. VCAM-1 RNA was readily detected in endothelial 
cells activated by TNF-o~. VCAM-1  RNA abundance was 
reduced by coincubation of activated endothelia with mela- 
noma cells  (Fig.  3).  This effect was maximal after 4 h and 
persisted for up to 48 h  (not shown). Thus,  the inhibition 
of VCAM-1 expression on endothelia regulated by the tumor 
is a consequence of diminished VCAM-1 RNA abundance. 
This might occur because of attenuated VCAM-1 transcrip- 
tion  or reduced VCAM-1 mRNA stability. 
VCAM-1 Downmodulation Occurs also in Human Malignan- 
cies.  To test whether this downregulatory effect of VCAM-1 
expression on endothelia occurs more generally in tumors, 
human melanoma and small cell carcinoma metastases in the 
lung were analyzed.  For the identification of endothelial cells, 
the tissues were stained with anti-factor VIII (Fig. 4). Normal 
venules within the lung expressed VCAM-1 (Fig. 4 c). Again, 
VCAM-1  expression was lost on blood vessels within  the 
metastatic lesion (Fig. 4 d). Suppression of VCAM-1 expres- 
sion was also observed on blood vessels within three primary 
melanomas  and three primary mamma carcinoma (not shown). 
Taken together,  these data show that downregulation  of 
the endothelial cell adhesion molecule VCAM-1 might rep- 
resent a common mechanism occurring in melanoma and car- 
cinoma metastases in humans. 
Discussion 
Our studies show that metastases of melanoma and carci- 
noma cells downregulate cytokine-induced VCAM-1 expres- 
sion on vascular endothelial cells. We were able to demon- 
strate a downregulation of the VCAM-1 message within 4 h, 
followed by a decrease of VCAM-1 protein expression on the 
endothelial cell surface after 24 h in an in vitro assay. This 
is a novel demonstration of a tumor-derived activity that in- 
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Figure  2.  Surface  expression of 
VCAM-1 on endothelial cells co- 
cultured with melanoma cells, after 
TNF-c~ treatment:  evaluation by 
cytofluorimetry. Co-cultured  calls 
were treated as described in Mate- 
rials and Methods. (A and B) Back- 
ground labding as assessed with 
control rat IgG, followed by fluo- 
rescein-conjugated secondary anti- 
body;  (C and D) bEnd.3 cells la- 
beled by anti VCAM-1 mAb M/K 
2.7;  (E) bEnd.3  cells co-cultured 
with B16 melanoma cells on the 
other side of the Nucleopore mem- 
brane for 24 h and stained by anti 
VCAM-1; and (F) bEnd.3 cells co- 
cultured  with 3T3 murine fibro- 
blasts for 24 h and stained by anti 
VCAM-1. One representative out 
of three independent  experiments 
is shown. 
814  Endothelial  Vascular Cell Adhesion Molecule 1 Suppressed by Melanoma Figure  3.  Analysis  ofVCAM-1 mRMA expression 
in endothelial cells co-cultured with melanoma cells 
after TNF-o~  treatment: evaluation  by RT-PCR. BEnd.3 
endothelioma cells were cultured on Nucleopore  filters, 
either alone (-), or with B16 melanoma cells (+) on 
the other side of the filter. After 4 h of incubation, 
endothelial cells were collected, and RNA was iso- 
lated  and  reversibly transcribed  into  cDNA.  The 
VCAM-1 and HPRT specific  cDNAs were amplified 
by PCR. (M): molecular size marker, (4D): no DNA 
control. 
hibits the expression of a cell adhesion molecule instrumental 
for the  accumulation  of blood-borne  leukocytes. 
VCAM-1  expression  on  vascular  endothelial  cells  was 
affected by the tumor on small but not on large vessels. In- 
deed, lymphocyte emigration from the blood to tissues occurs 
in  specialized regions,  the  small postcapillary venules  (10). 
Influencing  cell  adhesion  molecules  at  this  site  directly 
influences the tra~cking of lymphocytes into injured tissue. 
VCAM-1 is implicated in the tight adhesion and transmigra- 
tion steps of the adhesion cascade. Lack of VCAM-1 expres- 
sion abrogates lymphocyte extravasation (11).  Inhibition  of 
lymphocyte extravasation  may be a  strategy of tumors,  ir- 
respective of their  metastatic potential,  to escape immuno- 
logical  attack. 
The question then arises, whether such direct downregula- 
tory activities from tumors can be generalized and eventually 
expanded  to  other  endothelial  cell  adhesion  molecules  im- 
portant  for the  arrest  and  extravasation  of leukocytes.  Re- 
cently, it was observed that E-selectin expression was repressed 
in melanomas (12). E-selectin is an endothelial cell adhesion 
molecule responsible for the initial tethering  and rolling of 
leucocytes along the vascular endothelium.  Downregulation 
Figure  4.  Expression  of VCAM-1 in normal and malignant human lung endothelia. A small-cell  bronchial carcinoma of a 68-yr-old, male patient 
was analyzed. Frozen sections (5/~m) were labeled by specific antibodies and developed with alkaline phosphatase--coupled  secondary antibodies. (a) 
Staining of endothelial cells in a tumor-flee area with anti-factor VIII. (b) Factor VIII staining of venules within the-carcinoma lesion. (c) VCAM-1 
staining of vessels in the tumor-free area using the mAb BBA5. (d) VCAM-1 staining of vessels within  a carcinoma metastasis. (Arrows) Arterioles 
and venules in normal and metastatic tissue. The result represents one representative  of a total of seven  individual tumors analyzed. One to three sections 
per tumor were inspected. Original magnification:  x160, bar, 22/~m. 
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cytokine TGF3-1 (13). Although B16 melanoma cells release 
TGF3-1, this cytokine had no effect on VCAM-1 expression 
when added to stimulated endothelioma cells (our unpub- 
lished results) and this agrees with data reported by others (14). 
It seems that the ability of tumor cells to downregulate 
lymphocytic adhesiveness in tumor-draining vessels is not a 
particular property of the tumors analyzed here.  Using in- 
travital microscopy, lymphocyte adherence to blood vessels 
in  mammary  adenocarcinomas  in  rats  was  found  to  be 
significantly diminished (15). When fluorescently labeled lym- 
phocytes were transferred together with proinflammatory 
cytokines, the lymphocytes showed the characteristic rolling 
along and adhesion to vascular endothelia, which, however, 
was not the case in blood vessels within tumor metastases. 
Although the role of cell adhesion molecules has not been 
investigated in these studies,  tumor-dependent downregula- 
tion is certainly a possibility to be taken into consideration. 
Such a mechanism may in fact represent a common strategy 
of vascularized  melanoma and carcinoma metastases  to es- 
cape attack by cytotoxic effector cells. 
Clearly, these findings are of relevance with regard to the 
design of cell transfer immunotherapy  in cancer patients. One 
would expect successful therapeutic effects only with tumors 
that do not interfere with cell adherence receptors  on vas- 
cular endothelia. On the other hand, cytotoxic effector cells 
which use adhesion receptor-ligand combinations not con- 
trolled by tumor cells may be considered for therapy. Experi- 
ments examining the relationship between tumor-seeking 
effector cells and cell adhesion molecules available on tumor- 
associated vascular endothelia are currently in progress  (7). 
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